CPDD 78th Annual Scientific Meeting Program

Tuesday, June 14, 2016
87 Methadone patients in patient-centered treatment: One-year arrest data
S. M. Kelly 1 , K. E. O’Grady 2 , J. Gryczynski 1 , S. G. Mitchell 1 , J. H. Jaffe 1,3 , R. P. Schwartz 1 ,
1
Friends Research Institute, Baltimore, MD, 2 Univ. of MD, College Park, MD, 3 Univ. of MD,
School of Medicine, Baltimore, MD
88 Addictive behaviors and psychiatric comorbidities of incarcerated women in a French overseas
territory
L. Techer 3 , J. Alexandre 2 , D. Mété 3 , M. Auriacombe 2 , M. Fatseas 2 , 2 Addiction Psychiatry
(CNRS USR 3413), Universite Bordeaux, Bordeaux, France, 3 Addiction Treatment Center,
CHU Ile de la Réunion, Saint Denis, France
THEORETICAL
89 The quest to extend health services to vulnerable substance users in Rio de Janeiro, Brazil, in
the context of an unfolding economic crisis
N. Krawczyk 3 , D. Kerrigan 2 , F. I. Bastos 1 , 1 ICICT, Oswaldo Cruz Foundation, Rio de
Janeiro, Brazil, 2 Health Behavior and Society, Johns Hopkins Bloomberg School of Public
Health, Baltimore, MD, 3 Mental Health, Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD
90 Parallel growth modeling to better understand co-addiction: A randomized clinical trial of
tobacco smoking and stimulant use
M. Mamey 1 , L. Burns 1 , C. Barbosa-Leiker 2 , C. Parks 1 , S. McPherson 2 , 1 Psychology,
Washington State University, Pullman, WA, 2 College of Nursing, Washington State
University, Spokane, WA
91 Dealing with zero-numerators in estimating drug-dependence chances: A Bayesian approach
O. A. Vsevolozhskaya 3 , F. A. Wagner 2 , J. C. Anthony 1 , 1 Michigan State University, East
Lansing, MI, 2 PSRC, Morgan State University, Baltimore, MD, 3 Biostatistics, University of
Kentucky, Lexington, KY
92 Statistical assessment of abuse-deterrent opioids
L. Chen, FDA/CDER, Silver Spring, MD
93 A theory of social roles in addiction and recovery suitable for dynamic simulation modeling
E. Stringfellow, Brown School of Social Work, Washington University in St. Louis, St.
Louis, MO
94 Driving impairment of CNS prescription and non-prescription drugs
T. Hopyan 2 , R. Mann 1,3 , C. Wickens 1,3 , 1 Center for Addiction & Mental Health, Toronto, ON,
Canada, 2 INC Research, Toronto, ON, Canada, 3 University of Toronto, Toronto, ON, Canada
95 Assessing the abuse potential of botanical substances
K. Bonson, A. Trachtenberg, M. Klein, Controlled Substance Staff, Food and Drug
Administration, Silver Spring, MD
96 Pre-clinical abuse testing applications in drug development
J. Randall-Thompson, M. Klein, Controlled Substance Staff, Food and Drug Administration,
Silver Spring, MD
97 FDA role in the drug scheduling process of a drug under development
S. N. Calderon, D. Chiapperino, M. Klein, CDER/CSS, Food and Drug Administration, Silver
Spring, MD
98 Assessment of the abuse potential and benefits of kratom and its mitragynine alkaloids:
Implications for regulation
R. K. Lanier 1 , R. V. Fant 2 , E. Cone 2 , J. Henningfield 2 , 1 US Naturals, Washington, DC, 2 Pinney
Associates, Bethesda, MD
63